News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,415 Results
Type
Article (41338)
Company Profile (265)
Press Release (688796)
Multimedia
Podcasts (91)
Webinars (21)
Section
Business (204836)
Career Advice (2032)
Deals (35581)
Drug Delivery (128)
Drug Development (81509)
Employer Resources (173)
FDA (16505)
Job Trends (14981)
News (346805)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (47)
Adcomms (26)
Allergies (171)
Alliances (49579)
ALS (210)
Alzheimer's disease (1787)
Antibody-drug conjugate (ADC) (442)
Approvals (16881)
Artificial intelligence (654)
Autoimmune disease (286)
Automation (56)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (220)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (745)
Cancer (5771)
Cardiovascular disease (466)
Career advice (1724)
Career pathing (42)
CAR-T (328)
CDC (56)
Celiac Disease (3)
Cell therapy (887)
Cervical cancer (47)
Clinical research (70758)
Collaboration (2039)
Company closure (5)
Compensation (1385)
Complete response letters (79)
COVID-19 (2741)
CRISPR (107)
C-suite (1110)
Cystic fibrosis (152)
Data (7795)
Decentralized trials (3)
Denatured (27)
Depression (160)
Dermatology (84)
Diabetes (585)
Diagnostics (6920)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (315)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (281)
Earnings (91996)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119413)
Executive appointments (1076)
FDA (20203)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1708)
Gene editing (232)
Generative AI (55)
Gene therapy (715)
GLP-1 (1050)
Government (4729)
Grass and pollen (6)
Guidances (408)
Healthcare (18991)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (286)
Immuno-oncology (92)
Indications (190)
Infectious disease (3078)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16667)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (99)
Layoffs (562)
Leadership (39)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (759)
Lymphoma (429)
Machine learning (59)
Management (59)
Manufacturing (1039)
MASH (185)
Medical device (13922)
Medtech (14041)
Mergers & acquisitions (20155)
Metabolic disorders (1492)
mRNA (204)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (411)
Neuropsychiatric disorders (105)
Neuroscience (3285)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (78)
Obesity (698)
Opinion (286)
Ovarian cancer (218)
Pain (251)
Pancreatic cancer (297)
Parkinson's disease (357)
Partnered (33)
Patents (592)
Patient recruitment (666)
Peanut (62)
People (59551)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22058)
Phase 2 (31172)
Phase 3 (23198)
Pipeline (8568)
Policy (314)
Postmarket research (2568)
Preclinical (9396)
Press Release (64)
Prostate cancer (295)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1067)
Real estate (5969)
Recruiting (70)
Regulatory (25366)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3638)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (450)
Women's health (124)
Worklife (20)
Date
Today (178)
Last 7 days (909)
Last 30 days (3527)
Last 365 days (30208)
2026 (12167)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (348)
Arkansas (14)
Asia (39655)
Australia (6502)
California (13194)
Canada (3737)
China (1330)
Colorado (566)
Connecticut (572)
Delaware (401)
Europe (85809)
Florida (1970)
Georgia (421)
Hawaii (3)
Idaho (62)
Illinois (1045)
India (89)
Indiana (598)
Iowa (23)
Japan (532)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1581)
Massachusetts (9407)
Michigan (361)
Minnesota (712)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (141)
New Hampshire (84)
New Jersey (3467)
New Mexico (29)
New York (3442)
North Carolina (1671)
North Dakota (9)
Northern California (6612)
Ohio (396)
Oklahoma (23)
Oregon (41)
Pennsylvania (2650)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5201)
Tennessee (209)
Texas (2090)
United States (46503)
Utah (392)
Vermont (1)
Virginia (320)
Washington D.C. (80)
Washington State (1055)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
730,415 Results for "azitra inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Azitra, Inc. Announces Presentation at the 2024 BIO International Convention
Azitra, Inc. today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California.
May 31, 2024
·
4 min read
Pharm Country
Azitra, Inc. Announces Reverse Stock Split - June 27, 2024
Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.
June 27, 2024
·
4 min read
Drug Development
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
Azitra, Inc. today announced preclinical data from the Company’s platform and pipeline.
May 17, 2024
·
5 min read
Pharm Country
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported financial results for the three months ended March 31, 2024, and provided a business update.
May 9, 2024
·
10 min read
Business
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
Azitra, Inc. today reported financial results for the full year ended December 31, 2023, and provided a business update.
March 15, 2024
·
9 min read
Drug Development
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced preclinical data from the Company’s platform and pipeline.
April 22, 2024
·
4 min read
Drug Development
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced preclinical data from the Company’s platform and pipeline.
May 10, 2024
·
7 min read
Pharm Country
Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US
Azitra, Inc. announced that the U.S. Patent and Trademark Office has issued U.S. patent No. 11,850,267 covering future potential pipeline candidates for indications including ichthyosis vulgaris, titled “Methods and compositions for treating skin disease with recombinant microorganisms.” Travis Whitfill, Azitra’s COO, co-founder, and inventor of the patent stated, “Securing this patent is crucial for expanding our pipeline.
January 16, 2024
·
4 min read
Pharm Country
Azitra, Inc. Announces Pricing of Public Offering - February 14, 2024
Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.
February 13, 2024
·
3 min read
Pharm Country
Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced it will be presenting promising new preclinical data from its platform built to discover treatments for serious skin diseases at three upcoming scientific and medical conferences.
April 18, 2024
·
5 min read
1 of 73,042
Next
